TAUG - Tauriga Sciences Inc'.s E-Commerce Fulfillment Center Confirms Arrival of Black Currant Flavor Tauri-Gum Inventory
Black Currant Flavor Tauri-Gum™ is Cannabigerol Infused -Each Piece of Chewing Gum Contains 15mg CBG
NEW YORK, NY - (NewMediaWire) - August 6, 2020 - Tauriga Sciences, Inc.(OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating,diversified life sciences company, with a proprietary line of functional“supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon,Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologyinitiatives, today announced the arrival of Black Currant flavor Cannabigerol(“CBG”) infused Tauri-Gum™ inventory – at its E-Commerce fulfillmentcenter. This product is the Company’s second CBG version of Tauri-Gum™and is now available on the Company’s E-Commerce website (www.taurigum.com). Each piece of Black Currant chewing gumcontains 15mg CBG isolate – MSRP: $21.99 per Blister Pack.
Link to Black Currant CBG Tauri-Gum™ – E-Commerce Store:
https://taurigum.com/products/black-currant-cbd-gum-retail-box
Initial Production Run: Approximately 8,600 Blister Packs (860 Retail Boxes)
The Company has been experiencing strong levels of interestin its Black Currant flavor Tauri-Gum™ product, from a broad array of potentialcustomers and retailers. The product is Kosher Certified, VeganFormulated, Lab Tested, NON-GMO, Allergen Free, Gluten Free, NO THC, and 100%Made in the USA
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating,diversified life sciences company, engaged in several major business activitiesand initiatives. The company manufactures and distributes severalproprietary retail products and product lines, mainly focused on theCannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™,consists of a proprietary supplement chewing gum that is both Kosher certifiedand Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange,Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon). The Company’s commercialization strategyconsists of a broad array of retail customers, distributors, and a fast-growingE-Commerce business segment (E-Commerce website: www.taurigum.com).Please visit our corporate website, for additional information, as well asinquiries, at www.tauriga.com
Complementary to the Company’s retail business, are its twoongoing biotechnology initiatives. The first one relates to thedevelopment of a Pharmaceutical grade version of Tauri-Gum™, for nausearegulation (specifically designed to help patients that are subjected toongoing chemotherapy treatment). On March 18, 2020, the Company announcedthat it filed a provisional U.S. patent application covering its pharmaceuticalgrade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. isTitled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OFTREATMENT”. The second one relates to a collaboration agreement withAegea Biotechnologies Inc. for the co-development of a rapid, multiplexed,Novel Coronavirus (COVID-19) test with superior sensitivity andselectivity.
The Company is headquartered in New York City and operates aregional office in Barcelona, Spain. In addition, the Company operates afull time E-Commerce fulfillment center located in LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-lookingstatements” as defined by the Private Securities Litigation Reform Act of 1995which represent management’s beliefs and assumptions concerning future events.These forward-looking statements are often indicated by using words such as“may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” orplans, and may include statements regarding corporate objectives as well as theattainment of certain corporate goals and milestones. Forward-looking statementsare based on present circumstances and on management’s present beliefs withrespect to events that have not occurred, that may not occur, or that may occurwith different consequences or timing than those now assumed or anticipated.Actual results may differ materially from those expressed in forward looking statements due to known andunknown risks and uncertainties, such as are not guarantees of general economicand business conditions, the ability to successfully develop and marketproducts, consumer and business consumption habits, the ability to consummatesuccessful acquisition and licensing transactions, fluctuations in exchangerates, and other factors over which Tauriga has little or no control. Many ofthese risks and uncertainties are discussed in greater detail in the “RiskFactors” section of Tauriga’s Form 10-K and other filings made from time totime with the Securities and Exchange Commission. Such forward-lookingstatements are made only as of the date of this release, and Tauriga assumes noobligation to update forward-looking statements to reflect subsequent events orcircumstances. You should not place undue reliance on these forward-lookingstatements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:@taurigum
Twitter:@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com